Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Anlotinib is a novel multi-targeted tyrosine kinase inhibitor with activity against soft tissue sarcoma, small cell lung cancer, and non-small cell lung cancer (NSCLC). Potentiating the anticancer effect of anlotinib in combination strategies remains a clinical challenge. Metformin is an oral agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhongling, Jiang, Teng, Suo, Huirong, Xu, Shan, Zhang, Cai, Ying, Guoguang, Yan, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373262/
https://www.ncbi.nlm.nih.gov/pubmed/34421608
http://dx.doi.org/10.3389/fphar.2021.712181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373262/
https://www.ncbi.nlm.nih.gov/pubmed/34421608
http://dx.doi.org/10.3389/fphar.2021.712181

Ejemplares similares